ClinicalTrials.gg
CompletedNCT07851987Updated Oct 1, 2026

Pediatric Rhabdomyolysis in the Pediatric Intensive Care Unit: A Retrospective Cohort Study

An observational study in Rhabdomyolysis, sponsored by Hannover Medical School. Completed at 1 site in Germany. Open to participants aged Up to 20 Years. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Hannover Medical School · Observational

How we know

Updated Oct 1, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
55
Ages
Up to 20 Years
Sex
All
01

Study summary

This retrospective observational cohort study aims to evaluate the clinical characteristics, causes, intensive care management, and outcomes of pediatric patients with rhabdomyolysis admitted to the Pediatric Intensive Care Unit (PICU) at Hannover Medical School between 2007 and 2020. The study uses routinely collected clinical data from medical records without any study-related intervention or additional patient contact.

The primary objective is to identify factors associated with acute kidney injury, mortality, organ failure, and intensive care resource utilization. In addition, the study aims to develop a prognostic score to support early risk stratification of critically ill children with rhabdomyolysis. The findings may improve the understanding of this rare condition and support future clinical decision-making.

Read the detailed description

Rhabdomyolysis is a rare but potentially life-threatening condition in children characterized by skeletal muscle injury and the release of intracellular components into the circulation. Clinical presentation ranges from mild disease to severe complications, including acute kidney injury, multiple organ dysfunction, and death. Current evidence is limited because most published studies are based on small retrospective case series, and prognostic factors for critically ill pediatric patients remain insufficiently characterized.

This is a single-center, retrospective observational cohort study conducted at the Department of Pediatric Cardiology and Intensive Care Medicine, Hannover Medical School, Germany. The study includes pediatric patients treated in the Pediatric Intensive Care Unit (PICU) between January 1, 2007, and December 31, 2020, with a diagnosis of rhabdomyolysis. Clinical, laboratory, and treatment data are extracted from routinely collected electronic medical records. No study-related interventions are performed, and no additional patient contact takes place.

The study aims to characterize the etiology, clinical course, intensive care resource utilization, and outcomes of pediatric rhabdomyolysis in routine clinical practice. Furthermore, routinely collected clinical and laboratory parameters will be evaluated to develop a prognostic model for early risk stratification of acute kidney injury and mortality in critically ill children. The results are expected to improve the understanding of this rare disease and provide evidence to support future clinical management and research.

02

Conditions studied

  • Rhabdomyolysis

Keywords

  • rhabdomyolysis
  • acute kidney injury
  • pediatric intensive care
  • children
  • prognostic model
  • mortality
  • dialysis
  • myoglobin
  • creatininkinase
03

In context

Rhabdomyolysis

40 studies on the registry are indexed under Rhabdomyolysis; 5 are open to participants now.

This study's enrollment of 55 is below the median of 150 across 23 observational studies indexed under Rhabdomyolysis.

Browse Rhabdomyolysis studies →

Lead sponsor

Hannover Medical School is the lead sponsor of 202 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 20 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consisted of pediatric patients admitted to the Pediatric Intensive Care Unit (PICU) at Hannover Medical School, Germany, between January 1, 2007, and December 31, 2020. Eligible patients were identified retrospectively from routinely collected electronic hospital records. The cohort represents children treated for rhabdomyolysis at a tertiary care university hospital

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pediatric patients admitted to the Pediatric Intensive Care Unit (PICU) at Hannover Medical School, Germany, between January 1, 2007, and December 31, 2020.
  • ICD-10 diagnosis codes: M62.2 (non-traumatic muscle necrosis) or T79 (traumatic rhabdomyolysis)
  • Peak serum creatine kinase (CK) concentration ≥1,000 IU/L.
  • Availability of complete clinical data required for retrospective analysis.

Exclusion criteria

Exclusion Criteria:

  • Peak serum creatine kinase (CK) concentration \< 1,000 IU/L.
  • Incomplete clinical data preventing retrospective analysis.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
55 participants (actual)
Patient registry
No

Groups and cohorts

  • Pediatric patients with rhabdomyolysis

    Pediatric patients with rhabdomyolysis admitted to the Pediatric Intensive Care Unit (PICU) at Hannover Medical School between January 1, 2007, and December 31, 2020, who fulfilled the predefined eligibility criteria and were included in the final retrospective analysis. Clinical data were obtained from routinely collected medical records.

06

What researchers measure

Primary outcomes

  1. Acute Kidney Injury (AKI)

    Occurrence of acute kidney injury during PICU admission, defined according to the pediatric Risk, Injury, Failure, Loss, End-stage renal disease (pRIFLE) criteria.

    Time frame: From PICU admission until PICU discharge ( an average of 18 days)

  2. Mortality

    All-cause mortality during PICU admission.

    Time frame: From PICU admission until PICU discharge ( an average of 18 days)

  3. Organ Failure

    Occurrence of organ failure during the PICU stay based on predefined clinical and laboratory criteria, including respiratory, renal, hepatic, cardiovascular, and multiple organ failure.

    Time frame: From PICU admission until PICU discharge ( an average of 18 days)

  4. Duration of invasive mechanical ventilation

    Duration of invasive mechanical ventilation during PICU admission.

    Time frame: From initiation of invasive mechanical ventilation until discontinuation (up to PICU discharge, in the median 7 days).

  5. Length of PICU stay

    Length of stay in the pediatric intensive care unit

    Time frame: From PICU admission until PICU discharge ( an average of 18 days)

  6. Requirement for renal replacement therapy

    Requirement for renal replacement therapy during PICU admission

    Time frame: From PICU admission until PICU discharge ( an average of 18 days)

Secondary outcomes

  1. Peak creatine kinase (CK)

    Highest serum creatine kinase (CK) concentration recorded on each PICU day and used for longitudinal statistical analyses.

    Time frame: From PICU admission until PICU discharge ( an average of 18 days)

  2. Peak myoglobin

    Highest serum myoglobin concentration recorded on each PICU day and used for longitudinal statistical analyses

    Time frame: From PICU admission until PICU discharge ( an average of 18 days)

  3. Etiology of rhabdomyolysis

    Distribution of the underlying causes of rhabdomyolysis in the study population.

    Time frame: Baseline (PICU admission)

  4. Multiple organ involvement

    Presence of multiple organ involvement during PICU stay.

    Time frame: From PICU admission until PICU discharge ( an average of 18 days)

  5. Comorbidities

    Pre-existing medical conditions associated with pediatric rhabdomyolysis.

    Time frame: Baseline (PICU admission)

  6. Systemic inflammatory response syndrome (SIRS) or sepsis

    Occurrence of systemic inflammatory response syndrome (SIRS) or sepsis according to the International Pediatric Sepsis Consensus Conference criteria.

    Time frame: From PICU admission until PICU discharge ( an average of 18 days)

  7. Pediatric Index of Mortality II (PIM II)

    Disease severity at PICU admission assessed using the Pediatric Index of Mortality II (PIM II). PIM II estimates the predicted probability of mortality (%) in pediatric intensive care patients. Higher percentages indicate a higher predicted risk of death and greater disease severity.

    Time frame: Baseline (PICU admission)

  8. Pediatric Risk of Mortality III (PRISM III)

    Disease severity at PICU admission assessed using the Pediatric Risk of Mortality III (PRISM III) score. The PRISM III score ranges from 0 to 74 points, with higher scores indicating greater disease severity and a higher predicted risk of mortality.

    Time frame: Baseline (PICU admission)

07

Study locations

1 site
  • Hannover Medical School
    Hanover, Lower Saxony 30625, Germany
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared because this retrospective observational study uses pseudonymized patient data collected during routine clinical care. Data sharing is restricted by institutional policies, ethical requirements, and applicable data protection regulations (including the General Data Protection Regulation [GDPR]).

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2025 to primary completion in Dec 2025, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2026
First posted
Oct 1, 2026
StartActual
Jul 1, 2025
Primary completionActual
Dec 31, 2025
CompletionActual
Mar 30, 2026
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07851987
Responsible party
Sponsor
First posted
Oct 1, 2026
Start date
Jul 1, 2025
Primary completion
Dec 31, 2025
Completion
Mar 30, 2026
Last update
Oct 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion